FDA says Vertex hepatitis drug is highly effective

Apr 26, 2011

(AP) -- Federal health officials say a highly anticipated hepatitis C drug from Vertex Pharmaceuticals successfully treats a clear majority of patients in less time than older medicines that have been used for 20 years.

The posted its review of Vertex's telaprevir ahead of a meeting Thursday where outside experts will vote on the benefits of the drug. On Wednesday the experts will review a similar drug from Merck.

Both new drugs work by blocking the enzyme protease, which allows the hepatitis virus to reproduce. The new approach represents a breakthrough from older medicines, which are designed to help the fight hepatitis.

FDA scientists said 79 percent of patients who added telaprevir to older medicines were virus free six months after treatment.

Explore further: Merck, Iowa firm sign Ebola vaccine licensing deal (Update)

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA says Merck drug successfully fights hepatitis

Apr 25, 2011

Federal health officials said Monday a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years. But the agency has questions ...

New treatment for hepatitis C

May 14, 2008

Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology.

New hope for hepatitis C, an often hidden disease

Jan 17, 2011

There's new hope for an overlooked epidemic: Two powerful drugs are nearing the market that promise to help cure many more people of liver-attacking hepatitis C - even though most who have the simmering infection ...

Recommended for you

Powdered measles vaccine found safe in early clinical trials

8 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

neiorah
not rated yet Apr 26, 2011
Great, now the need for liver transplants will go down

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.